Immune Response News and Research

RSS

New trial examines the effectiveness of a two-pronged immunotherapy for glioblastomas

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.

25 Mar 2022

New insights into SARS-CoV-2 immunity gained from natural infection

Antibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COVID-19, according to a study published in the peer-reviewed journal Viral Immunology.

25 Mar 2022

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers evaluated the neutralizing antibody titers and anti-receptor-binding domain immunoglobulin G titers in sera of kidney transplant recipients who were vaccinated against COVID-19 and treated with 300 mg dosage of Evusheld™

25 Mar 2022

Impact of truncated open reading frame 8 protein variants of SARS-CoV-2

A new study identified unique truncated open reading frame 8 proteins among SARS-CoV-2 sequences.

25 Mar 2022

Researchers characterize vaccines for infectious bronchitis virus

A new study characterized the genetic and immunological aspects of the infectious bronchitis virus (IBV) vaccines commercially used in Korea.

25 Mar 2022

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A research paper published in the New England Journal of Medicine has demonstrated how a third dose of Pfizer-BioNTech (BNT162b2) vaccine administered in a median period of 10.8 months after the second one bestowed 95.3% efficacy against coronavirus disease 2019 (COVID-19), in comparison with two doses of the same vaccine during a median follow-up of 2.5 months.

24 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

A new study presented the differences among total anti-SARS-CoV-2 antibodies following SARS-CoV-2 Pfizer primary and booster vaccinations.

24 Mar 2022

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Researchers evaluated the effectiveness of a novel vaccine candidate UB-612 against 14 SARS-CoV-2 variants, including the latest variant of concern, Omicron.

24 Mar 2022

$Metabolic-immune interaction appears to be the cause of heart failure with preserved ejection fraction$

Metabolic-immune interaction appears to be the cause of heart failure with preserved ejection fraction

The dominant form of heart failure worldwide appears to be caused by a strong, bidirectional interaction between the body's response to metabolic stress and the immune system, according to a review article written by UT Southwestern researchers and colleagues.

23 Mar 2022

New therapy makes immunologically 'cold' tumors hot enough for immune attack

Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%.

23 Mar 2022

T-cell and neutralizing antibody response after a third COVID-19 vaccine dose in hemodialysis patients

Researchers compare the impact of a third mRNA COVID-19 vaccine in hemodialysis patients by measuring antibody levels and IFN-γ responses.

23 Mar 2022

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Researchers discuss alternate therapeutic targets for treating COVID-19 and the effects of Gal-9 on SARS-CoV-2 infection and the immune response.

23 Mar 2022

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

A recent study finds that there is no considerable B-cell immunity against SARS-CoV-2 in unexposed healthy individuals.

23 Mar 2022

New nanoparticle-based COVID-19 vaccine platform could target other infectious diseases

Just one dose of a new nanoparticle-based COVID-19 vaccine was enough to produce an immune response in animals on track with vaccines currently in clinical use.

23 Mar 2022

Study investigates germinal center of antibody-mediated immunity against SARS-CoV-2

In a new study, researchers explored the germinal center of antibody-mediated immunity towards SARS-CoV-2.

23 Mar 2022

New approach could lead to quicker generation of effective, personalized cancer vaccines

Scientists have created a pipeline for identifying, prioritizing and evaluating potential tumor antigens for the fast generation of cancer vaccines, according to a report published today in eLife.

22 Mar 2022

Novel nanoparticle-based COVID vaccines induce long-term neutralizing antibody response

Researchers report the results for a new SARS-CoV-2 vaccine currently in Phase III clinical trial known as I53-50.

22 Mar 2022

Rubella antibodies vs. COVID-19

A new study describes a potential relationship between antibody titers against the rubella virus and the severity of COVID-19.

22 Mar 2022

Function of glycolytic enzyme depends on its cellular localization

The function of the glycolytic enzyme hexokinase 1 differs depending on its location within the cell, according to a Northwestern Medicine study published in Molecular Cell.

22 Mar 2022

Immune Response News and Research

New trial examines the effectiveness of a two-pronged immunotherapy for glioblastomas

New insights into SARS-CoV-2 immunity gained from natural infection

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Impact of truncated open reading frame 8 protein variants of SARS-CoV-2

Researchers characterize vaccines for infectious bronchitis virus

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Metabolic-immune interaction appears to be the cause of heart failure with preserved ejection fraction

New therapy makes immunologically 'cold' tumors hot enough for immune attack

T-cell and neutralizing antibody response after a third COVID-19 vaccine dose in hemodialysis patients

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

New nanoparticle-based COVID-19 vaccine platform could target other infectious diseases

Study investigates germinal center of antibody-mediated immunity against SARS-CoV-2

New approach could lead to quicker generation of effective, personalized cancer vaccines

Novel nanoparticle-based COVID vaccines induce long-term neutralizing antibody response

Rubella antibodies vs. COVID-19

Function of glycolytic enzyme depends on its cellular localization

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News